T2 Biosystems Receives FDA Breakthrough Device Designation For Candida Auris Diagnostic Test
Portfolio Pulse from Benzinga Newsdesk
T2 Biosystems has received FDA Breakthrough Device Designation for its Candida Auris diagnostic test. This designation will expedite the development and review process of the test.
July 20, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
T2 Biosystems' stock may see positive movement due to the FDA Breakthrough Device Designation for its Candida Auris diagnostic test.
The FDA Breakthrough Device Designation is a significant regulatory milestone that can expedite the development and review process of a device. This could potentially lead to earlier market entry and revenue generation for T2 Biosystems, which may positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100